The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
Open accessAbstract
A subset of breast cancer patients benefits from preoperative bevacizumab and chemotherapy, but validated predictive biomarkers are lacking. Here, we aimed to evaluate tissue-based angiogenesis markers for potential predictive value regarding response to neoadjuvant bevacizumab treatment in breast cancer. In this randomized 1:1 phase II clinical trial, 132 patients with large or locally advanced HER2-negative tumors received chemotherapy ± bevacizumab. Dual Factor VIII/Ki-67 immunohistochemical staining was performed on core needle biopsies at baseline and week 12. Microvessel density (MVD), proliferative microvessel density (pMVD; Factor VIII/Ki-67 co-expression), glomeruloid microvascular proliferation (GMP), and a gene expression angiogenesis signature score, were studied in relation to pathologic complete response (pCR), clinico-pathologic features and intrinsic molecular subtype. We found that high baseline MVD (by median) significantly predicted pCR in the bevacizumab-arm (odds ratio 4.9, P = 0.012). High pMVD, presence of GMP, and the angiogenesis signature score did not predict pCR, but were associated with basal-like (P ≤ 0.009) and triple negative phenotypes (P ≤ 0.041). pMVD and GMP did also associate with high-grade tumors (P ≤ 0.048). To conclude, high baseline MVD significantly predicted response to bevacizumab treatment. In contrast, pMVD, GMP, and the angiogenesis signature score, did not predict response, but associated with aggressive tumor features, including basal-like and triple-negative phenotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The results on the histological class pairs associated with pCR and RD are in line with previously published studies.
“These results are in line with previously published studies [58–66].”
From Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer (2024) · cites this paper as [64]
The Results section reports that high baseline microvessel density was associated with pCR in the bevacizumab arm, but does not connect histological class pairs to pCR or residual disease. Searches for histological type, grade, and residual disease found no passage establishing the comparison attributed to this paper. Page numbers were unavailable in our copy. (LLM, conf=0.71)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,598
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K. D., Wang, M., Gralow, J. R., Dickler, M. N., Cobleigh, M., Perez, E. A., Shenkier, T. N., Cella, D. F., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,104
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,065
Robert, N. J., Dieras, V. C., Glaspy, J. A., Brufsky, A., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,063
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C., Tolaney, S. M., Kuzma, C. S., Pluard, T., Somlo, G., Port, E. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,017
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X. B., Tomczak, P., Delozier, T., Sohn, J., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 896
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
von Minckwitz, G., Eidtmann, H., Rezai, M., Fasching, P. A., Tesch, H., Eggemann, H., Schrader, I., Kittel, K., Hanusch, C. A., Kreienberg, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111065 · Cited by 529
Microvessel Density as a Prognostic Factor in Women with Breast Cancer
Uzzan, B., Nicolas, P., Cucherat, M., & Perret, G. Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1957 · Cited by 470
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Robidoux, A., Atkins, J. N., Báez-Díaz, L., Brufsky, A., Mehta, R. S., Fehrenbacher, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111097 · Cited by 460
Markers of Response for the Antiangiogenic Agent Bevacizumab
Lambrechts, D., Lenz, H., de Haas, S., Carmeliet, P., & Scherer, S. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2762 · Cited by 341
Tolaney, S. M., Boucher, Y., Duda, D. G., Martin, J. D., Seano, G., Ancukiewicz, M., Barry, W. T., Goel, S., Lahdenrata, J., Isakoff, S. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518808112 · Cited by 258
Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets
Nagy, J. A., & Dvorak, H. F. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9500-6 · Cited by 163
Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Liu, Q., Robidoux, A., Báez-Díaz, L., Brufsky, A., Mehta, R. S., Fehrenbacher, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00041-8 · Cited by 154
Earl, H. M., Hiller, L., Dunn, J., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Abraham, J., Thomas, J. S. J., Provenzano, E., Hughes‐Davies, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70137-3 · Cited by 135
Macdonald, F., Ford, C. H. J., & Casson, A. G. (1997) · Nature Medicine · doi:10.1038/nm1097-1163b · Cited by 131
Vascular Proliferation Is Important for Clinical Progress of Endometrial Cancer
Stefansson, I. M., Salvesen, H. B., & Akslen, L. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1163 · Cited by 126
Self-citationBais, C., Mueller, B., Brady, M. F., Mannel, R. S., Burger, R. A., Wei, W., Marien, K. M., Kockx, M. M., Husain, A., Birrer, M. J., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx066 · Cited by 108
Straume, O., Chappuis, P. O., Salvesen, H. B., HALVORSEN, O. J., Haukaas, S. A., Goffin, J. R., Bégin, L. R., Foulkes, W. D., & Akslen, L. A. (2002) · PubMed · Cited by 101
Self-citationThe role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials
Roviello, G., Bachelot, T., Hudis, C. A., Curigliano, G., Reynolds, A. R., Petrioli, R., & Generali, D. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.026 · Cited by 95
Yang, S. X., Steinberg, S. M., Nguyen, D., Wu, T. D., Modrusan, Z. D., & Swain, S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4762 · Cited by 89
Nahleh, Z. A., Barlow, W. E., Hayes, D. F., Schott, A. F., Gralow, J. R., Sikov, W. M., Perez, E. A., Chennuru, S., Mirshahidi, H., Corso, S. W., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3889-6 · Cited by 87
Krüger, K., Stefansson, I. M., Collett, K., Arnes, J. B., Aas, T., & Akslen, L. A. (2012) · The Breast · doi:10.1016/j.breast.2012.07.008 · Cited by 66
Self-citationSilwal‐Pandit, L., Nord, S., Gythfeldt, H. V. D. L., Møller, E. K., Fleischer, T., Rødland, E. A., Krohn, M., Borgen, E., Garred, Ø., Olsen, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0160 · Cited by 55
Self-citationVascular proliferation is increased in basal-like breast cancer
Nalwoga, H., Arnes, J. B., Stefansson, I. M., Wabinga, H., Foulkes, W. D., & Akslen, L. A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1740-7 · Cited by 52
Self-citationMacdonald, F., Ford, C. H. J., & Casson, A. G. (2004) · Taylor & Francis eBooks · doi:10.4324/9780203503447 · Cited by 46
Vascular proliferation is a prognostic factor in breast cancer
Arnes, J. B., Stefansson, I. M., Straume, O., Baak, J. P. A., Lønning, P. E., Foulkes, W. D., & Akslen, L. A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1785-7 · Cited by 39
Self-citationSitohy, B., Chang, S.-H., Sciuto, T. E., Masse, E., Shen, M., Kang, P. M., Jaminet, S.-C. S., Benjamin, L. E., Bhatt, R. S., Dvořàk, A. M., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.06.010 · Cited by 37
Stefansson, I. M., Raeder, M. B., Wik, E., Mannelqvist, M., Kusonmano, K., Knutsvik, G., Haldorsen, I. S., Trovik, J., Oyan, A. M., Kalland, K.-H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3521 · Cited by 21
Self-citationAtezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC
Dhillon, S., & Syed, Y. Y. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00686-w · Cited by 21
Lindholm, E. M., Kristian, A., Nalwoga, H., Krüger, K., Nygård, S., Akslen, L. A., Mælandsmo, G. M., & Engebraaten, O. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.03.006 · Cited by 21
Self-citationvon der Lippe Gythfeldt, H., Lien, T., Tekpli, X., Silwal‐Pandit, L., Borgen, E., Garred, Ø., Skjerven, H., Schlichting, E., Lundgren, S., Wist, E., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33108 · Cited by 20
Self-citationAkslen, L. A., Straume, O., Geisler, S. B., Sørlie, T., Chi, J.-T., Aas, T., Børresen-Dale, A.-L., & Lønning, P. E. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.203 · Cited by 16
Self-citation
Flagged first, then by citations
1 of the 37 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Package delivered: folate receptor-mediated transporters in cancer therapy and diagnosis
Ahmadi, M., Ritter, C. A., von Woedtke, T., Bekeschus, S., & Wende, K. (2024) · Chemical Science · doi:10.1039/d3sc05539f · Cited by 106
Alternative Vascularization Mechanisms in Tumor Resistance to Therapy
Belotti, D., Pinessi, D., & Taraboletti, G. (2021) · Cancers · doi:10.3390/cancers13081912 · Cited by 53
Fisher, T. B., Saini, G., Rekha, T. S., Krishnamurthy, J., Bhattarai, S., Callagy, G., Webber, M., Janssen, E. A. M., Kong, J., & Aneja, R. (2024) · Breast Cancer Research · doi:10.1186/s13058-023-01752-y · Cited by 42
Ultrasound super-resolution imaging for differential diagnosis of breast masses
Zhang, G., Lei, Y.-M., Li, N., Yu, J., Jiang, X., Yu, M., Hu, H.-M., Zeng, S., Cui, X., & Ye, H.-R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1049991 · Cited by 37
Molecular perspective on targeted therapy in breast cancer: a review of current status
Cetinkaya, B. D., & Avcı, Ç. B. (2022) · Medical Oncology · doi:10.1007/s12032-022-01749-1 · Cited by 39
Lymphatic Endothelial Markers and Tumor Lymphangiogenesis Assessment in Human Breast Cancer
Chen, J., Luo, B., Ma, R., Luo, X., Chen, Y., & Li, Y. (2021) · Diagnostics · doi:10.3390/diagnostics12010004 · Cited by 30
Therapeutic targeting of the pituitary tumor microenvironment
Ilie, M. D., Alcubierre, D. D., Carretti, A. L., Jouanneau, E., & Raverot, G. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108506 · Cited by 25
Shahvandi, M. K., Soltani, M., Kashkooli, F. M., Saboury, B., & Rahmim, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-18723-6 · Cited by 24
Exosomal lncRNA SNHG12 promotes angiogenesis and breast cancer progression
Chen, Y., Zhou, Y., Chen, J., Yang, J., Yuan, Y., & Wu, W. (2024) · Breast Cancer · doi:10.1007/s12282-024-01574-6 · Cited by 24
Mei, J., Yang, K., Zhang, X., Luo, Z., Tian, M., Fan, H., Chu, J., Zhang, Y., Ding, J., Xu, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202409147 · Cited by 20
Heterogeneity of the Tumor Microenvironment Across Molecular Subtypes of Breast Cancer
Kashyap, D., Bal, A., Irinike, S., Khare, S., Bhattacharya, S., Das, A., & Singh, G. (2023) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001139 · Cited by 19
Ultrasound super-resolution imaging for non-invasive assessment of microvessel in prostate lesion
Huang, X., Ye, H., Hu, Y., Lei, Y., Tian, Y., Huang, X., Zhang, J., Zhang, Y., Gui, B., Liu, Q., et al. (2025) · Cancer Imaging · doi:10.1186/s40644-024-00819-z · Cited by 13
Calcium Homeostasis in the Development of Resistant Breast Tumors
Martín‐García, D., Téllez, T., Redondo, M., & García‐Aranda, M. (2023) · Cancers · doi:10.3390/cancers15112872 · Cited by 8
Hou, X., Li, Z., Liu, Y., Gao, J., & Song, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1662492 · Cited by 4
Development of a Microvessel Density Gene Signature and Its Application in Precision Medicine
Kuronishi, M., Ozawa, Y., Kimura, T., Li, S. D., & Kato, Y. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0403 · Cited by 3
Floryan, M. A., Cordiale, A., Jensen, H., Chen, J., Guo, Z., Vinayak, V., Kheiri, S., Raman, R., Shenoy, V. B., Cambria, E., et al. (2026) · Biofabrication · doi:10.1088/1758-5090/ae8721 · Cited by 2
Klingen, T. A., Chen, Y., Aas, H., & Akslen, L. A. (2024) · Human Pathology · doi:10.1016/j.humpath.2024.06.009 · Cited by 2
Self-citationApplication of Ultra Micro Angiography in Differential Diagnosis of Renal Tumors
Cheng, R., Peng, Y., Wang, Y., Li, S., Pan, X., Chen, S., Cheng, J., Huang, Y., Wei, L., Cui, X., et al. (2025) · Journal of Ultrasound in Medicine · doi:10.1002/jum.70165 · Cited by 1
Therapy for aggressive pituitary tumors and carcinomas
Ilie, M. D., Lamback, E. B., Gadelha, M. R., & Raverot, G. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10039-4 · Cited by 1
Tissue-Based Biomarkers of Tumor-Vascular Interactions
Akslen, L. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_2 · Cited by 1
Self-citationWik, E., Ingebriktsen, L. M., & Akslen, L. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_23
Self-citationMatsutani, A., Taruno, K., Akashi‐Tanaka, S., Yoshizawa, A., Nagata, A., Yamochi, T., Takimoto, M., Inoue, E., & Nakamura, S. (2022) · The Showa University Journal of Medical Sciences · doi:10.15369/sujms.34.125
(2023) · European Journal of Gynaecological Oncology · doi:10.22514/ejgo.2023.058
Phoenix, K. N., Singh, V., Murphy, P. A., & Claffey, K. P. (2026) · Breast Cancer Research · doi:10.1101/2025.06.23.661087
Kayadibi, Y., Esen, G., Kurt, S. A., Wetherilt, C. S., Ozturk, T. K., Icten, Y. N., & Taşkın, F. (2025) · Journal of Ultrasound in Medicine · doi:10.1002/jum.70022
Senescent Epithelial Cells Serve as Invasive Growth Drivers in Ameloblastoma
Lin, H. T., Liang, J.-J., Zhang, C., Man, Q., Li, R., Zhang, L., & Liu, B. (2025) · Laboratory Investigation · doi:10.1016/j.labinv.2025.104227
Super-Resolution Ultrasound Imaging of Oligodendroglioma: A Case Report and Literature Review
Liu, X., Song, X., Liu, C., & Zheng, Y. (2025) · Journal of Surgery · doi:10.11648/j.js.20251305.11
Fisher, T. B., Saini, G., Rekha, T. S., Krishnamurthy, J., Bhattarai, S., Callagy, G. M., Webber, M., Janssen, E. A. M., Kong, J., & Aneja, R. (2024) · Figshare · doi:10.6084/m9.figshare.25025860
Brandal, S. H. B., Mo, T., Fangberget, A., Nilsen, L. B., Geier, O. M., Bjørndal, H., Holmen, M. M., Engebråten, O., Garred, Ø., Hole, K. H., et al. (2026) · Cancers · doi:10.3390/cancers18030393
Self-citationGuo, Q., Wu, M., Li, J., Xu, G., Wu, X., Lu, X., Zhao, X., Li, G., Zhang, X., Li, X., et al. (2026) · Journal of Nanoparticle Research · doi:10.1007/s11051-026-06648-4
Zhou, C., Guo, Y., Meng, Z., Wan, K., Qin, J., & Wang, Y. (2026) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s563533
Metadata
- Authors
- Krüger, K., Silwal-Pandit, L., Wik, E., Straume, O., Stefansson, I. M., Borgen, E., Garred, Ø., Naume, B., Engebraaten, O., & Akslen, L. A.
- Affiliations
- Haukeland University Hospital (NO)
- Oslo University Hospital (NO)
- Corresponding author
- Akslen, Lars A.
- ORCID
- Venue
- Scientific Reports
- Published
- 2021-02-09
- Volume
- 11
- Issue
- 1
- Pages
- 3388-3388
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC7873274
- OpenAlex
- W3128705022
- Cited by
- 32
- References
- 37
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 2
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Sanofi
- Kreftforeningen (11003001)
- Helse Vest (223250)
- Universitetet i Bergen (223250)
- Norges Forskningsråd (223250, 191436/V50)
- Helse Sør-Øst RHF
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- microvessel density, bevacizumab, neoadjuvant therapy, locally advanced breast cancer, HER2-negative breast cancer, predictive biomarkers, angiogenesis, pathological complete response, triple-negative breast cancer, basal-like breast cancer, tumor grade
- MeSH terms
- Bevacizumab, Microvascular Density, Adult, Aged, Breast Neoplasms, Female, Humans, Male, Middle Aged, Neovascularization, Pathologic, Neoadjuvant Therapy, Biopsy, Large-Core Needle
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
